Comparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox®) versus thromboelastometry (ROTEM®)

Cristina Solomon, Herbert Schöchl, Marco Ranucci, Ulf Schött, Christoph J. Schlimp

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Whole blood viscoelastic tests such as the fibrin-based thromboelastometry (ROTEM®) test FIBTEM are increasingly used in the perioperative setting to quickly identify deficits in fibrin quality, and to guide hemostatic therapy. The recently developed FibScreen2 test of the ReoRox® method, based on free oscillation rheometry, also provides an evaluation of fibrin clot quality. To date, little information is available on the performance of this test in hemodiluted blood, by comparison to FIBTEM. Methods. Whole blood samples from eight healthy volunteers were analyzed using FIBTEM and Fibscreen2. Native and diluted (to 33% and 50% using saline, gelatin or hydroxyethyl starch [HES]) samples were analyzed. Clot strength parameters, including FIBTEM maximum clot firmness (MCF), FIBTEM maximum clot elasticity (MCE) and Fibscreen2 maximum elasticity (G'max), were measured. Results. In repeatedly measured samples from two volunteers, FIBTEM MCF and Fibscreen2 G'max revealed a coefficient of variation (CV) of 5.3 vs. 16.3% and 5.6 vs. 31.7% for each volunteer, respectively. Hemodilution decreased clot strength. Both Fibscreen2 G'max and FIBTEM parameters decreased proportionally to the dilution ratio when saline was used. The observed reductions in FIBTEM and Fibscreen2 parameters were more severe in samples diluted with gelatin and HES, compared to saline. Finally, a regression analysis between FIBTEM MCE and Fibscreen2 G'max revealed a poor goodness of fit (r2 = 0.37, p <0.0001). Conclusions. ReoRox® Fibscreen2 test has a high coefficient of variation, and its application in various hemodilution conditions showed limited comparability with the ROTEM® FIBTEM test.

Original languageEnglish
Pages (from-to)239-246
Number of pages8
JournalScandinavian Journal of Clinical and Laboratory Investigation
Volume75
Issue number3
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Thrombelastography
Elasticity
Fibrin
Hemodilution
Blood
Gelatin
Starch
Volunteers
Hematologic Tests
Hemostatics
Regression analysis
Dilution
Healthy Volunteers
Regression Analysis
Therapeutics

Keywords

  • Blood coagulation
  • Blood coagulation tests
  • Blood viscosity
  • Fibrin
  • Fibrinogen
  • Point-of-care systems

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Comparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox®) versus thromboelastometry (ROTEM®). / Solomon, Cristina; Schöchl, Herbert; Ranucci, Marco; Schött, Ulf; Schlimp, Christoph J.

In: Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 75, No. 3, 01.05.2015, p. 239-246.

Research output: Contribution to journalArticle

@article{f7b92d20a10a425f9942551825b6ff77,
title = "Comparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox{\circledR}) versus thromboelastometry (ROTEM{\circledR})",
abstract = "Background. Whole blood viscoelastic tests such as the fibrin-based thromboelastometry (ROTEM{\circledR}) test FIBTEM are increasingly used in the perioperative setting to quickly identify deficits in fibrin quality, and to guide hemostatic therapy. The recently developed FibScreen2 test of the ReoRox{\circledR} method, based on free oscillation rheometry, also provides an evaluation of fibrin clot quality. To date, little information is available on the performance of this test in hemodiluted blood, by comparison to FIBTEM. Methods. Whole blood samples from eight healthy volunteers were analyzed using FIBTEM and Fibscreen2. Native and diluted (to 33{\%} and 50{\%} using saline, gelatin or hydroxyethyl starch [HES]) samples were analyzed. Clot strength parameters, including FIBTEM maximum clot firmness (MCF), FIBTEM maximum clot elasticity (MCE) and Fibscreen2 maximum elasticity (G'max), were measured. Results. In repeatedly measured samples from two volunteers, FIBTEM MCF and Fibscreen2 G'max revealed a coefficient of variation (CV) of 5.3 vs. 16.3{\%} and 5.6 vs. 31.7{\%} for each volunteer, respectively. Hemodilution decreased clot strength. Both Fibscreen2 G'max and FIBTEM parameters decreased proportionally to the dilution ratio when saline was used. The observed reductions in FIBTEM and Fibscreen2 parameters were more severe in samples diluted with gelatin and HES, compared to saline. Finally, a regression analysis between FIBTEM MCE and Fibscreen2 G'max revealed a poor goodness of fit (r2 = 0.37, p <0.0001). Conclusions. ReoRox{\circledR} Fibscreen2 test has a high coefficient of variation, and its application in various hemodilution conditions showed limited comparability with the ROTEM{\circledR} FIBTEM test.",
keywords = "Blood coagulation, Blood coagulation tests, Blood viscosity, Fibrin, Fibrinogen, Point-of-care systems",
author = "Cristina Solomon and Herbert Sch{\"o}chl and Marco Ranucci and Ulf Sch{\"o}tt and Schlimp, {Christoph J.}",
year = "2015",
month = "5",
day = "1",
doi = "10.3109/00365513.2014.993698",
language = "English",
volume = "75",
pages = "239--246",
journal = "Scandinavian Journal of Clinical and Laboratory Investigation",
issn = "0036-5513",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Comparison of fibrin-based clot elasticity parameters measured by free oscillation rheometry (ReoRox®) versus thromboelastometry (ROTEM®)

AU - Solomon, Cristina

AU - Schöchl, Herbert

AU - Ranucci, Marco

AU - Schött, Ulf

AU - Schlimp, Christoph J.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background. Whole blood viscoelastic tests such as the fibrin-based thromboelastometry (ROTEM®) test FIBTEM are increasingly used in the perioperative setting to quickly identify deficits in fibrin quality, and to guide hemostatic therapy. The recently developed FibScreen2 test of the ReoRox® method, based on free oscillation rheometry, also provides an evaluation of fibrin clot quality. To date, little information is available on the performance of this test in hemodiluted blood, by comparison to FIBTEM. Methods. Whole blood samples from eight healthy volunteers were analyzed using FIBTEM and Fibscreen2. Native and diluted (to 33% and 50% using saline, gelatin or hydroxyethyl starch [HES]) samples were analyzed. Clot strength parameters, including FIBTEM maximum clot firmness (MCF), FIBTEM maximum clot elasticity (MCE) and Fibscreen2 maximum elasticity (G'max), were measured. Results. In repeatedly measured samples from two volunteers, FIBTEM MCF and Fibscreen2 G'max revealed a coefficient of variation (CV) of 5.3 vs. 16.3% and 5.6 vs. 31.7% for each volunteer, respectively. Hemodilution decreased clot strength. Both Fibscreen2 G'max and FIBTEM parameters decreased proportionally to the dilution ratio when saline was used. The observed reductions in FIBTEM and Fibscreen2 parameters were more severe in samples diluted with gelatin and HES, compared to saline. Finally, a regression analysis between FIBTEM MCE and Fibscreen2 G'max revealed a poor goodness of fit (r2 = 0.37, p <0.0001). Conclusions. ReoRox® Fibscreen2 test has a high coefficient of variation, and its application in various hemodilution conditions showed limited comparability with the ROTEM® FIBTEM test.

AB - Background. Whole blood viscoelastic tests such as the fibrin-based thromboelastometry (ROTEM®) test FIBTEM are increasingly used in the perioperative setting to quickly identify deficits in fibrin quality, and to guide hemostatic therapy. The recently developed FibScreen2 test of the ReoRox® method, based on free oscillation rheometry, also provides an evaluation of fibrin clot quality. To date, little information is available on the performance of this test in hemodiluted blood, by comparison to FIBTEM. Methods. Whole blood samples from eight healthy volunteers were analyzed using FIBTEM and Fibscreen2. Native and diluted (to 33% and 50% using saline, gelatin or hydroxyethyl starch [HES]) samples were analyzed. Clot strength parameters, including FIBTEM maximum clot firmness (MCF), FIBTEM maximum clot elasticity (MCE) and Fibscreen2 maximum elasticity (G'max), were measured. Results. In repeatedly measured samples from two volunteers, FIBTEM MCF and Fibscreen2 G'max revealed a coefficient of variation (CV) of 5.3 vs. 16.3% and 5.6 vs. 31.7% for each volunteer, respectively. Hemodilution decreased clot strength. Both Fibscreen2 G'max and FIBTEM parameters decreased proportionally to the dilution ratio when saline was used. The observed reductions in FIBTEM and Fibscreen2 parameters were more severe in samples diluted with gelatin and HES, compared to saline. Finally, a regression analysis between FIBTEM MCE and Fibscreen2 G'max revealed a poor goodness of fit (r2 = 0.37, p <0.0001). Conclusions. ReoRox® Fibscreen2 test has a high coefficient of variation, and its application in various hemodilution conditions showed limited comparability with the ROTEM® FIBTEM test.

KW - Blood coagulation

KW - Blood coagulation tests

KW - Blood viscosity

KW - Fibrin

KW - Fibrinogen

KW - Point-of-care systems

UR - http://www.scopus.com/inward/record.url?scp=84929304408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929304408&partnerID=8YFLogxK

U2 - 10.3109/00365513.2014.993698

DO - 10.3109/00365513.2014.993698

M3 - Article

C2 - 25598348

AN - SCOPUS:84929304408

VL - 75

SP - 239

EP - 246

JO - Scandinavian Journal of Clinical and Laboratory Investigation

JF - Scandinavian Journal of Clinical and Laboratory Investigation

SN - 0036-5513

IS - 3

ER -